Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine

Abstract

There is currently no standardized serum bactericidal antibody (SBA) assay for evaluating immune responses to meningococcal outer membrane vesicle or protein vaccines. Four laboratories, Manchester Health Protection Agency (MC HPA), New Zealand Institute of Environmental Science and Research Limited (NZ ESR), Norwegian Institute of Public Health (NIPH), and Chiron Vaccines (Chiron), measured SBA titers in the same panel of human sera (n=76) from laboratory staff (n=21) vaccinated with MenBvac. Blood samples were collected prevaccination, prior to each of the three doses of MenBvac given at 6-week intervals, and 6 weeks following the third dose. Initial results showed a number of discrepancies in results between the four participating laboratories. The greatest effect on titers appeared to be due to differences among laboratories in the maintenance of the meningococcal serogroup B test strain, 44/76-SL. A repeat study was conducted using the same frozen isolate (meningococcal serogroup B test strain 44/76-SL), freshly distributed to all four laboratories. Using SBA titers from the tilt method for all samples, and using MC HPA as the comparator, the results were as follows for NZ ESR, NIPH, and Chiron, respectively, using log(10) titers: correlation coefficients (r) were 0.966, 0.967, and 0.936; intercepts were 0.08, 0.15, and 0.17; and slopes were 0.930, 0.851, and 0.891. In both prevaccination and postvaccination samples from 15 subjects assayed by all four laboratories, similar increases in SBA (fourfold or greater) were observed (for 11, 11, 9, and 9 subjects for MC HPA, NZ ESR, NIPH, and Chiron, respectively), and similar percentages of subjects with SBA titers of>or=4 p revaccination and 6 weeks following each dose were found. The SBA assay has been harmonized between the four different laboratories with good agreement on seroconversion rates, n-fold changes in titers, and percentages of subjects with SBA titers of >or=4.

FIG. 1.

Comparison of SBA titers from repeat study (n = 76) between NZ ESR and MC HPA (a), NIPH and MC HPA (b), and Chiron and MC HPA (c), with regression of y equivalent to log₁₀(titer from first laboratory in the pair) on x equivalent to log₁₀(titer from second laboratory in the pair).

FIG. 1.

Comparison of SBA titers from repeat study (n = 76) between NZ ESR and MC HPA (a), NIPH and MC HPA (b), and Chiron and MC HPA (c), with regression of y equivalent to log₁₀(titer from first laboratory in the pair) on x equivalent to log₁₀(titer from second laboratory in the pair).

FIG. 1.

Comparison of SBA titers from repeat study (n = 76) between NZ ESR and MC HPA (a), NIPH and MC HPA (b), and Chiron and MC HPA (c), with regression of y equivalent to log₁₀(titer from first laboratory in the pair) on x equivalent to log₁₀(titer from second laboratory in the pair).